Search

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.

Read more

EHA Awards 2011 at the 16th Congress of EHA in London

Bob Löwenberg will be the fourth recipient of the Jean Bernard Lifetime Achievement Award which was presented for the first time at the 13th Annual Congress in Copenhagen.

Read more

Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients

Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.

Read more

1st European EHA Sickle Cell Conference

EHA is teaming up with the Annual Scientific Conference on Sickle Cell and Thalassaemia, 2020 and the British Society of Haematology (BSH) to co-organize this first European Sickle Cell Conference; and also as a result of COVID-19 offer it as…

Read more

Professor Degos awarded at the 17th Congress of EHA in Amsterdam

Professor Degos has made a major contribution, to our understanding of the pathogenesis and treatment of acute promyelocytic leukemia (APL), to international public health and to the EHA.

Read more

Appointment of new EHA Managing Director

The Hague (Netherlands), January 16, 2023. The European Hematology Association (EHA) is pleased to welcome its new Managing Director, Ignacio Quiles Lara, who took up the post on January 9.

Read more